Compare Gilead Sciences, Inc. (GILD) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Li Auto Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Li Auto Inc trades at $11.4 (market cap $10.83B). The key difference: Gilead Sciences, Inc. is far larger — about 16.8× Li Auto Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Li Auto Inc for 101 Days on average.
| GILD | LI | |
|---|---|---|
Market Cap | $182.09B | $10.83B |
Volume | 4,960,247 | 2,002,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $23.61 |
52-Week Low | $116.74 | $10.69 |
Typical Hold Time | 111 Days | 101 Days |
Enterprise Value | $205.15B | $258.87M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Li Auto (LI) trades at $10.90, near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal revenue contraction from $144.5B (2024) to $112.3B (2025) and negative net margins. Recent vehicle launches (Li i9, MEGA) aim to counter competitive pressures in China's EV market, but cash flow trends show operational challenges with -$8.6B operating cash flow in 2025.
Outlook remains challenged by execution risks and market saturation, though analyst consensus target of $15.18 suggests 39% upside. Key risks include persistent cash burn, intense domestic competition, and macroeconomic headwinds. The valuation appears reasonable with P/S of 0.73, but profitability recovery is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
